We compared outcomes of adult patients receiving T-cell-depleted (TCD) hematopoietic SCT (HCT) without additional GVHD prophylaxis at Memorial Sloan Kettering Cancer Center (MSKCC, N = 52), with those of patients receiving conventional grafts at MD Anderson Cancer Center (MDACC, N = 115) for ALL in CR1 or CR2. Patients received myeloablative conditioning. Thirty-nine patients received anti-thymocyte globulin at MSKCC and 29 at MDACC. Cumulative incidence of grades 2-4 acute (P = 0.001, 17.3% vs 42.6% at 100 days) and chronic GVHD (P = 0.006, 13.5% vs 33.4% at 3 years) were significantly lower in the TCD group. The non-relapse mortality at day 100, 1 and 3 years was 15.4, 25.0 and 35.9% in the TCD group and 9.6, 23.6 and 28.6% in the unmodified group (P = 0.368). There was no difference in relapse (P = 0.107, 21.3% vs 35.5% at 3 years), OS (P = 0.854, 42.6% vs 43.0% at 3 years) or RFS (P = 0.653, 42.8% vs 35.9% at 3 years). In an adjusted model, age 450, cytogenetics and CR status were associated with inferior RFS (hazard ratio (HR) = 2.16, P = 0.003, HR = 1.77, P = 0.022, HR = 2.47, Po 0.001), whereas graft type was NS (HR = 0.90, P = 0.635). OS and RFS rates are similar in patients undergoing TCD or conventional HCT, but TCD effectively reduces the rate of GVHD.
INTRODUCTION
Allogeneic hematopoietic SCT (HCT) has been shown to confer a survival advantage to patients with high-risk ALL in first CR1 and in patients in second CR (CR2), with OS at 5 years of 40-50%. [1] [2] [3] [4] [5] GVHD remains one of the main causes of post-transplant morbidity and mortality. Manipulation of allografts with T-cell depletion (TCD) has established efficacy in patients with AML, myelodysplastic syndrome and non-Hodgkin lymphoma, and is associated with a significantly decreased incidence of GVHD. [6] [7] [8] [9] [10] A recent comparison of conventional and TCD grafts in patients with AML demonstrated similar outcomes but significantly less GVHD in patients receiving TCD grafts. 11 The use of TCD-HCT was also recently reported in patients with ALL (n = 56), and demonstrated favorable OS and relapse-free survival (RFS) with low rates of GVHD. 4 However, there are no published reports comparing TCD vs conventional transplantation in ALL.
In this study, we compared the outcomes of patients receiving TCD-HCT at Memorial Sloan Kettering Cancer Center (MSKCC), with patients receiving conventional grafts at MD Anderson Cancer Center (MDACC) for ALL in CR1 or CR2, and found that OS and RFS were similar, but acute and chronic GVHD incidences were significantly lower in the TCD group.
PATIENTS AND METHODS Patients
Patients older than 18, undergoing HCT for ALL in CR1 or CR2 between 2000 and 2010, were identified through the institutional BMT registries at MDACC and MSKCC after approval by each institution's institutional review board. Patient demographics, disease characteristics, treatment, GVHD and outcome data were obtained from departmental databases at each institution. CR was defined as ⩽ 5% blasts in the BM. Cytogenetic risk was assigned according to standard criteria.
12 Donor-recipient HLA matching was established by DNA sequence-specific oligonucleotide typing for HLA-A, -B, Cw, -DQB1 and -DRB1 loci, in both institutions. Patients were considered to be mismatched if they did not match at 10/10 alleles.
Transplant procedure and supportive care
Patients at MSKCC received TCD grafts (TCD group, n = 52) after myeloablative cytoreduction, consisting of hyperfractionated TBI, followed by thiotepa and high dose CY (n = 16) or thiotepa and fludarabine (n = 31), as described previously. 6, 7, 9 One patient was treated with BU, melphalan and fludarabine, as previously described, 8 and four with clofarabine, thiotepa and melphalan, as part of an ongoing clinical trial (clinicaltrials. gov NCT01119066). PB stem cell (PBSC) grafts (n = 46) underwent CD34 + cell selection using CliniMACS cell selection system (Miltenyi Biotech, Gladbach, Germany, n = 7), or by positive selection of CD34 + cells using the ISOLEX 300i Magnetic Cell Separator (Baxter, Deerfield, IL, USA) and subsequent sheep RBC rosette depletion (n = 39). 7 T cells were removed from BM grafts (n = 6) by sequential soybean lectin agglutination and sheep RBC rosette depletion. 6, 8 Thirteen recipients of an HLA-matched related donor graft who were treated with hyperfractionated TBI, thiotepa and fludarabine (n = 10), or hyperfractionated TBI, thiotepa and CY (n = 3) did not receive any rejection prophylaxis. Thirty-nine patients received anti-thymocyte globulin (ATG) for graft-rejection prophylaxis. Eight recipients of matched related identical donors received ATG either because they received chemotherapy only conditioning (n = 4) or at the discretion of the practicing providers for recipients of TBI-based conditioning (n = 4). No patients received GVHD prophylaxis post transplant.
Patients at MDACC received unmodified grafts (unmodified group, n = 115) after myeloablative conditioning regimens as follows: 62 patients received TBI-based conditioning with either CY (n = 44) or etoposide (n = 18), 51 i.v. BU-based conditioning with either melphalan (n = 31) or clofarabine (n = 20), and two received BEAM and alemtuzumab. Recipients of matched unrelated grafts received a total dose of 4 mg/kg ATG (n = 29). Tacrolimus and mini-MTX (5 mg/m 2 on days 1, 6 and 11 post transplant) were used for GVHD prophylaxis in all patients. Forty patients received BM grafts, and 75 PBSC.
Patients were managed at both institutions according to each institution's standard guidelines. GVHD was diagnosed clinically, confirmed pathologically when possible and graded according to standard criteria. 13 GVHD diagnosed after day 100 post transplant was classified as chronic GVHD.
14 Only patients who engrafted were evaluable for GVHD assessment. The cause of death was determined using a standard algorithm. 15 Data collection and statistical methods Data was updated as of December 2012. Patient characteristics were compared between the TCD and unmodified graft groups using the Wilcoxon rank sum test for continuous covariates, and Χ 2 -test or Fisher's exact test for categorical covariates where appropriate. OS and RFS were defined as the time from HCT until death from any cause and disease relapse or death, respectively. Non-relapse mortality was defined as death in a patient without leukemia relapse. Univariate probabilities and 95% confidence intervals of OS and RFS were estimated using Kaplan-Meier methodology, and survival distributions were compared across patient and treatment characteristics using a log-rank test. The cumulative incidence of non-relapse mortality, leukemia relapse and GVHD was estimated on the basis of cumulative incidence method of competing risks. Leukemia relapse, death in the absence of leukemia relapse and relapse or death in the absence of GVHD were considered competing risks for non-relapse mortality, leukemia relapse and GVHD, respectively. Gray's test was used to compare the incidence of non-relapse mortality, leukemia relapse and GVHD between patients receiving unmodified vs TCD grafts. The incidence of relapse for the two graft types was additionally compared separately for CR1 and CR2 patients. Cox proportional hazards regression was used to evaluate the univariate associations between patient and transplant characteristics with respect to OS and RFS. Patient and transplant characteristics included, type of graft (TCD, unmodified), age (older than 50 years), gender, immunophenotype (B cell, T cell, other), cytogenetic risk, CR status at transplantation (CR1, CR2), donor type (HLA-matched related, HLA-matched unrelated, HLA-mismatched) and stem cell source (BM, PB). A multivariate Cox regression model was implemented to further investigate the association between risk of relapse or death and graft type, CR status, age and cytogenetics. Statistical analysis was performed using R 3.0.0.
RESULTS

Patient characteristics
Patient characteristics are summarized in Table 1 . Donor type differed between the unmodified and TCD groups, with a higher percentage of patients in the unmodified group, receiving a transplant from a matched related donor and only one patient in this group receiving a transplant from a mismatched donor (P o 0.001). In addition, a higher percentage of patients received grafts from PB in the TCD cohort compared with the unmodified group (88.5% vs 65.2%, P = 0.003). As in vivo TCD with alemtuzumab or ATG could affect outcomes in the unmodified graft group, we compared the use of in vivo TCD within this group and found no significant difference with respect to OS and RFS (data not shown). As a result, all patients in the unmodified group were pooled for subsequent analysis except for GVHD. OS, RFS and relapse incidence As of December 2012, the median follow-up among surviving patients was 38.9 months (range: 20.5-97.4 months) in the TCD group and 47.9 months (6.0-126.1 months) in the unmodified group. No statistically significant difference was observed between the TCD and unmodified groups with respect to OS and RFS ( Figure 1 , Table 2 ). The 3-year survival probabilities in the TCD and unmodified groups were 42.6% vs 43.0% (P = 0.854) for OS and 42.8% vs 35.9% for RFS (P = 0.653), respectively. The 3-year cumulative incidence of relapse was 21.3% in the TCD group and 35.5% in the unmodified group (P = 0.107). Separated by CR status, Counts (percents) based on total possible individuals receiving TKI.
T-cell-depleted vs unmodified Allo-HCT for ALL GS Hobbs et al the incidence of relapse remained lower for the TCD cohort; however, neither comparison reached statistical significance (CR1: P = 0.261, 3-year estimates 16.7% vs 29.0%; CR2: P = 0.431, 3-year estimates 32.3% vs 42.5%).
Non-relapse mortality The non-relapse mortality at day 100, 1 year and 3 years was 15.4, 25.0 and 35.9% in the TCD group and 9.6, 23.6 and 28.6% in the unmodified group (P = 0.368), respectively. Causes of death in the TCD group included relapsed leukemia (n = 11, 37.9%), GVHD (n = 5, 17.2%), infection (n = 7, 24.1%), organ toxicity (n = 5, 17.2%), and graft failure (n = 1, 3.4%). In the unmodified group, causes of death included relapse (n = 34, 51.5%), GVHD (n = 21, 31.8%), infection (n = 8, 12.1%) and organ toxicity (n = 3, 4.5%). Death in the first 100 days post transplant occurred in nine (17.3%) patients in the TCD group (four from infection, one acute GVHD (aGVHD), one non-engraftment, two organ failure, one relapse) and 11 (9.6%) patients in the unmodified group (four from infection, six from aGVHD, one from organ toxicity). Patients in the unmodified group had a lower incidence of death owing to infection than the patients in the TCD group (P = 0.046). 
GVHD
The rate of grade 2-4 aGVHD was significantly lower in the TCD group than in the unmodified group (P = 0.001, 100 day estimates 17.3% vs 42.6%). No significant difference was noted in the rate of grade 3-4 aGVHD, which was low in both cohorts (P = 0.164, 100 day estimates 7.7% vs 15.7% in the TCD and conventional groups, respectively). The rate of chronic GVHD was significantly lower in the TCD group compared with the unmodified group (P = 0.006, 3-year estimates 13.5% vs 33.4%). In the unmodified group, 39 patients developed chronic GVHD, including 26 with extensive cGVHD, whereas seven patients in the TCD group developed chronic GVHD, including three with extensive cGVHD. Owing to potential differences in aGVHD incidence among patients receiving ATG, a subset analysis was conducted looking at the grade 2-4 aGVHD incidence among patients who received ATG. A significant difference remained between TCD and unmodified grafts with TCD grafts exhibiting a significantly lower incidence of aGVHD 2-4 (23.1% vs 55.2% at 100 days, P = 0.005). Among patients receiving ATG, the TCD group exhibited a lower incidence of chronic GVHD compared with the unmodified group (P = 0.100, 3-year estimates 17.9% vs 32.3%).
Use of tyrosine kinase inhibitors Tyrosine kinase inhibitors (TKIs) were administered to a subset of patients with Philadelphia chromosome-positive ALL at both centers. At MDACC, 13 patients out of 46 Philadelphia chromosome-positive patients (28.3%) received TKI therapy (all with imatinib) and at MSKCC, 5 out of 22 patients (22.7%) received TKI therapy (three with imatinib, two with dasatinib). There was no significant difference between Philadelphia chromosome-positive patients that received TKI and those who did not receive a TKI with respect to OS, RFS, aGVHD or cGVHD.
Prognostic factors
In the univariate analyses shown in Table 3 , age 450 and CR status increased both the risk of death (hazard ratio (HR) = 2.08, P = 0.003 and HR = 1.55, P = 0.034) and the risk of relapse or death (HR = 1.95, P = 0.005 and HR = 1.55, P = 0.029). No other factor achieved statistical significance at the 0.05 level. In a multivariate model shown in Table 4 , age 450 (HR = 2.41, P = 0.001 and HR = 2.16, P = 0.003) and CR2 status (HR = 2.26, P = 0.002 and HR = 2.47, P o0.001) were associated with an inferior OS and RFS, respectively, poor risk cytogenetics was also associated with inferior RFS (HR = 1.77, P = 0.022). There was no association between graft type and OS or RFS (HR 1.039, P = 0.869 and HR = 0.90, P = 0.635, respectively).
DISCUSSION
Our results represent the first published comparison of TCD vs conventional graft transplantation solely in ALL. A randomized, prospective study done by the Unrelated Donor Marrow Transplantation Trial compared patients with a variety of hematologic malignancies, TCD only achieved a 1 log reduction and necessitated post-transplant CYA. 16 Thus, our study is the largest, albeit retrospective, comparison of outcomes of different graft sources in ALL. OS was similar between the two groups. However, the cumulative incidences of relapse, grades 2-4 GVHD and cGVHD were lower in the TCD group.
Improvements in supportive care, the use of reduced intensity conditioning and more accurate HLA typing contribute to decreased treatment-related mortality with allogeneic transplantation. TCD potentially represents an important advance towards further reducing toxicity from transplantation, mainly in the form of decreased GVHD. Few reports exist comparing outcomes for these two transplantation strategies. 11, 17 We recently reported outcomes of patients receiving TCD vs conventional grafts for AML and showed similar findings, primarily a reduced incidence of GVHD without adversely affecting relapse or survival.
11
There are few publications about TCD transplantation in ALL. Patel et al. 18 reported on long-term outcomes of 48 patients receiving in vivo TCD grafts with alemtuzumab for patients with poor risk Ph-ALL in CR1. Outcomes were favorable, with OS at 5 years of 61%, aGVHD of 27% and cGVHD at 5 years of 22%. The largest report to date of TCD transplantation in ALL (n = 56) was recently published by Goldberg et al., 4 with a 2-year OS of 39% and incidence of GVHD of 20% at 1 year, without any grade 4 GVHD reported. In addition, a significant proportion of patients in this series had high-risk cytogenetic features. These reports, along with our current study, add to the growing body of literature, suggesting that TCD is a safe and effective transplantation strategy.
The current study does have some limitations. The retrospective nature of the study is an inherent limitation. The patients in each treatment group were not homogeneous and included patients on clinical trials, which may be associated with selection bias. Furthermore, a variety of conditioning regimens were used. Although data is missing for the induction and consolidation therapy patients received, there is likely variation in this regard as well. In addition, post-transplant maintenance with TKIs was variably used in both centers for Philadelphia chromosomepositive patients, although not significantly different between the two centers. Finally, CR was defined by the absence of blasts. Normalization of blood counts and minimal residual disease were not taken into account, and thus our comparison of relapse rates between the two transplant approaches may be limited.
Our study also challenges the applicability of findings from recent studies showing that PBSCT is associated with higher rates of GVHD when compared with BM after ablative conditioning. 19 In our study, patients at MSKCC almost exclusively received PBSC (88.5%), compared with MDACC where 34.8% of patients received BM. However, the rates of GVHD at MSKCC were significantly lower. It is likely that the protective benefit of TCD with respect to the occurrence of GVHD outweighs the benefit of BM as a graft source. A recent Center for International Blood and Marrow Transplant Research (CIBMTR) study evaluated the outcomes of T-cell-depleted vs unmodified Allo-HCT for ALL GS Hobbs et al patients with ALL receiving cord blood, PBSC and BM grafts. 20 Similar rates of aGVHD were seen in patients receiving PBSC and BM grafts, with lower rates in the cord blood group, and similar rates of cGVHD regardless of graft source. In addition to demonstrating comparable outcomes in the cord blood group compared with the PBSC and BM groups, this study suggests that all three graft sources are acceptable for patients with ALL. In addition to more patients receiving PBSCT, patients in the TCD group were significantly more likely to receive a mismatched graft (30.8% vs 0.9%). Despite this, GVHD rates were significantly Abbreviations: CI = confidence interval; HR = hazard ratio; RFS = relapse-free survival; TCD = T-cell depletion. Abbreviations: CI = confidence interval; HR = hazard ratio; RFS = relapse-free survival; TCD = T-cell depletion.
